Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SNDX Syndax Pharmaceuticals

Pre-Market Trading 04-09 07:18:51 EDT

10.56

-0.45

-4.09%

盘前10.00

-0.56-5.30%

04:21 EDT

High11.70	Low10.36	Vol2.45M
Open11.32	D1 Closing11.01	Amplitude12.17%
Mkt Cap908.42M	Tradable Cap815.10M	Total Shares86.02M
T/O26.35M	T/O Rate3.17%	Tradable Shares77.19M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"SNDX","market":"US","secType":"STK","nameCN":"Syndax Pharmaceuticals","latestPrice":10.56,"timestamp":1744142400000,"preClose":11.01,"halted":0,"volume":2448498,"hourTrading":{"tag":"盘前","latestPrice":10,"preClose":10.56,"latestTime":"04:21 EDT","volume":1,"amount":10,"timestamp":1744186890377},"delay":0,"floatShares":77187856,"shares":86024394,"eps":-3.722848,"marketStatus":"Pre-Market Trading","change":-0.45,"latestTime":"04-09 07:18:51 EDT","open":11.32,"high":11.7,"low":10.36,"amount":26350096.806498,"amplitude":0.121708,"askPrice":11.33,"askSize":4,"bidPrice":10,"bidSize":499,"shortable":3,"etf":0,"ttmEps":-3.722848,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1744205400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1456981200000,"exchange":"NASDAQ","adjPreClose":10.56,"preHourTrading":{"tag":"盘前","latestPrice":10,"preClose":10.56,"latestTime":"04:21 EDT","volume":1,"amount":10,"timestamp":1744186890377},"postHourTrading":{"tag":"盘后","latestPrice":10.56,"preClose":10.56,"latestTime":"16:05 EDT","volume":18393,"amount":194230.08,"timestamp":1744142707816},"volumeRatio":1.1846443686245387,"impliedVol":0.6259,"impliedVolPercentile":0.6},"requestUrl":"/m/hq/s/SNDX","defaultTab":"news","newsList":[{"id":"2525370197","title":"BRIEF-Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525370197","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525370197?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 04:23","pubTimestamp":1743798228,"startTime":"0","endTime":"0","summary":"BRIEF-Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)April 4 (Reuters) - Syndax Pharmaceuticals Inc SNDX.O:SYNDAX PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nTUA9GPLFT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2525573742","title":"Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525573742","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525573742?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 04:05","pubTimestamp":1743797100,"startTime":"0","endTime":"0","summary":"NEW YORK, April  04, 2025  (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/04/3056191/0/en/Syndax-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","LU2210150020.SGD","IE00BGHQF748.EUR","SNDX","NVIW.SI","LU2210149790.SGD","TQQQ","IE00B3QW5Z07.USD","NDAQ","MNQmain","BK4139","USJW.SI","PSQ","NQmain","IE00B64PRP62.GBP","TSYW.SI","BK4112",".IXIC","USAW.SI","IE00BKPKM429.USD","QLD","BK4588","QID","SQQQ","BK4585"],"gpt_icon":1},{"id":"2524546679","title":"Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2524546679","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524546679?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 19:00","pubTimestamp":1743591600,"startTime":"0","endTime":"0","summary":"NEW YORK, April 02, 2025  -- Syndax Pharmaceuticals , a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:30 a.m. ET.A live webcast of the fireside chat will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.Syndax Pharmaceuticalsis a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj , an FDA-approved menin inhibitor, and Niktimvo , an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1  receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the ful","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/syndax-announces-participation-stifel-2025-110000411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNDX","BK4139","BK4179","SF","FET","BK4127"],"gpt_icon":0},{"id":"2520905463","title":"Syndax Pharmaceuticals Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2520905463","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520905463?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 23:01","pubTimestamp":1742482860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 11:01 ET (15:01 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2517921920","title":"Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517921920","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517921920?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 05:05","pubTimestamp":1741208700,"startTime":"0","endTime":"0","summary":"NEW YORK, March  05, 2025  (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/05/3037749/0/en/Syndax-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4139","SQQQ","NDAQ",".IXIC","TQQQ","BK4588","QID","BK4585","USAW.SI","IE00B64PRP62.GBP","NVIW.SI","USJW.SI","QLD","MNQmain","IE00BKPKM429.USD","TSYW.SI","LU2095319765.USD","PSQ","SNDX","NQmain","LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2517945165","title":"Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2517945165","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517945165?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 23:00","pubTimestamp":1741186831,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.Syndax Pharmaceuticals Inc  reported its first quarter with product revenue, generating $7.7 million from Revv Forge in just five weeks post-launch.The FDA approved Revv Forge, a first-in-class mein inhibitor, for relapse refractory acute leukemia patients with KMT2A translocation, highlighting the company's strong execution and rapid market entry.The company is aggressively advancing its clinical development strategy for Revv Forge, with plans to file a supplemental new drug application to expand its indicated population.Syndax Pharmaceuticals Inc  has launched Nick Timbo in partnership with Insight, targeting chronic graft versus host disease, and is exploring further expansion opportunities.The competitive landscape in oncology is evolving, and Syndax Pharmaceuticals Inc  faces challenges in maintaining its first-mover advantage.A: Steve Kloster, Chief Commercial Officer, noted that o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/syndax-pharmaceuticals-inc-sndx-q4-150031279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNDX"],"gpt_icon":0},{"id":"2517595400","title":"Positive Outlook on Syndax Pharmaceuticals: Strong Market Presence and Strategic Growth Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2517595400","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517595400?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 12:55","pubTimestamp":1741150548,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Salim Syed has maintained their bullish stance on SNDX stock, giving a Buy rating yesterday. Salim Syed has given his Buy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-on-syndax-pharmaceuticals-strong-market-presence-and-strategic-growth-initiatives?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-on-syndax-pharmaceuticals-strong-market-presence-and-strategic-growth-initiatives?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"1129854279","title":"Stock Track | Syndax Pharmaceuticals Plunges 8.91% Amid Disclosed Risks to Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1129854279","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129854279?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 01:58","pubTimestamp":1741111110,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals  stock plummeted 8.91% in intraday trading on Tuesday, following the company's disclosure of new risks that could impact its revenue growth prospects.According to the company's filing, Syndax faces challenges in navigating regulatory hurdles and unfavorable market conditions, which could hinder its ability to drive revenue growth. These disclosed risks have introduced uncertainties around the company's future financial performance and growth trajectory, prompting investors","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SNDX"],"gpt_icon":0},{"id":"2517604457","title":"Syndax Pharmaceuticals Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2517604457","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517604457?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 01:11","pubTimestamp":1741108260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2025 12:11 ET (17:11 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2516675336","title":"B. Riley Cuts Price Target on Syndax Pharmaceuticals to $29 From $36, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2516675336","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516675336?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:50","pubTimestamp":1741092607,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals (SNDX) has an average rating of buy and mean price target of $36.29, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SNDX","RILY"],"gpt_icon":0},{"id":"2516780406","title":"Scotiabank Remains a Hold on Syndax Pharmaceuticals (SNDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516780406","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516780406?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:19","pubTimestamp":1741090741,"startTime":"0","endTime":"0","summary":"Scotiabank analyst George Farmer maintained a Hold rating on Syndax Pharmaceuticals (SNDX – Research Report) today and set a price target of $16.00...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/scotiabank-remains-a-hold-on-syndax-pharmaceuticals-sndx-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/scotiabank-remains-a-hold-on-syndax-pharmaceuticals-sndx-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNDX","BK4141","MMAT","BK4139"],"gpt_icon":0},{"id":"2516062729","title":"Syndax Pharmaceuticals Price Target Maintained With a $51.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2516062729","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516062729?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 19:42","pubTimestamp":1741088520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SNDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2025 06:42 ET (11:42 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2516276876","title":"Syndax Pharmaceuticals Inc : Citigroup Cuts Target Price to $42 From $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2516276876","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516276876?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 19:38","pubTimestamp":1741088301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0P3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SNDX"],"gpt_icon":0},{"id":"2516629410","title":"Barclays Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516629410","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516629410?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 18:07","pubTimestamp":1741082865,"startTime":"0","endTime":"0","summary":"Barclays analyst Peter Lawson maintained a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report) today and set a price target of $33.00. Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-buy-rating-on-syndax-pharmaceuticals-sndx-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-buy-rating-on-syndax-pharmaceuticals-sndx-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNDX"],"gpt_icon":0},{"id":"1145265910","title":"Stock Track | Syndax Pharmaceuticals Plunges 8.27% in Pre-Market Amid Revenue Growth Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=1145265910","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145265910?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 17:24","pubTimestamp":1741080260,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Inc.  stock plummeted 8.27% in Tuesday's pre-market session, indicating a lower open for the biopharmaceutical company's shares.The pre-market plunge comes as Syndax disclosed new risks related to its revenue growth prospects. According to the company's disclosure, it faces challenges in navigating regulatory hurdles and market conditions that could impact its ability to drive revenue growth.Investors appear to be reacting negatively to these disclosed risks, which introdu","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Syndax Pharmaceuticals Plunges 8.27% in Pre-Market Amid Revenue Growth Challenges","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SNDX"],"gpt_icon":0},{"id":"2516617759","title":"Syndax Pharmaceuticals: Navigating Revenue Growth Amidst Regulatory and Market Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2516617759","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516617759?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 14:02","pubTimestamp":1741068144,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Inc. (SNDX) has disclosed a new risk, in the Accounting & Financial Operations category. Syndax Pharmaceuticals Inc. faces a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/syndax-pharmaceuticals-navigating-revenue-growth-amidst-regulatory-and-market-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/syndax-pharmaceuticals-navigating-revenue-growth-amidst-regulatory-and-market-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNDX"],"gpt_icon":0},{"id":"2516150776","title":"Syndax Pharmaceuticals Reports 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516150776","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516150776?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 11:59","pubTimestamp":1741060743,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Inc. ( ($SNDX) ) has released its Q4 earnings. Here is a breakdown of the information Syndax Pharmaceuticals Inc. presented ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/syndax-pharmaceuticals-reports-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/syndax-pharmaceuticals-reports-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2516656665","title":"BUZZ-Syndax Pharmaceuticals drops on wider quarterly loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2516656665","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516656665?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 01:08","pubTimestamp":1741021708,"startTime":"0","endTime":"0","summary":"BUZZ-Syndax Pharmaceuticals drops on wider quarterly loss** Shares of drug developer Syndax Pharmaceuticals SNDX.O fall 5% to $14.86** Co posts Q4 net loss of $94.2 million, compared to $72.5 million a year ago ** Reports Q4 operating expenses of $96.4 million, compared to $77.91 million a year ago ** Co reports Q4 sales of $7.7 mln for its first commercial product, Revuforj, chemically known as revumenib, to treat a type of blood cancer** Expects to seek regulatory approval for revumenib to treat a type of cancer that starts in bone marrow in Q2 2025** SNDX's shares have fallen 35% in the last 12 months  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL3N3PM16Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","BK4139"],"gpt_icon":0},{"id":"2516630528","title":"Syndax Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2516630528","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516630528?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 23:25","pubTimestamp":1741015500,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummarySyndax Pharmaceuticals Inc SNDX.OQ reported a quarterly adjusted loss of $1.10 per share for the quarter ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL5N3PM1FA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX"],"gpt_icon":0},{"id":"2516598630","title":"Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2516598630","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516598630?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 21:15","pubTimestamp":1741007703,"startTime":"0","endTime":"0","summary":"Syndax Pharmaceuticals  came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.08. This compares to loss of $1 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.85%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.13 per share when it actually produced a loss of $0.98, delivering a surprise of 13.27%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/syndax-pharmaceuticals-sndx-reports-q4-131503867.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SNDX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.syndax.com","stockEarnings":[{"period":"1week","weight":-0.1207},{"period":"1month","weight":-0.2131},{"period":"3month","weight":-0.2353},{"period":"6month","weight":-0.4198},{"period":"1year","weight":-0.537},{"period":"ytd","weight":-0.2012}],"compareEarnings":[{"period":"1week","weight":-0.115},{"period":"1month","weight":-0.1379},{"period":"3month","weight":-0.1578},{"period":"6month","weight":-0.1383},{"period":"1year","weight":-0.0429},{"period":"ytd","weight":-0.1529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.047367},{"month":2,"riseRate":0.666667,"avgChangeRate":0.081651},{"month":3,"riseRate":0.555556,"avgChangeRate":0.051247},{"month":4,"riseRate":0.3,"avgChangeRate":-0.014593},{"month":5,"riseRate":0.444444,"avgChangeRate":0.006686},{"month":6,"riseRate":0.555556,"avgChangeRate":0.008456},{"month":7,"riseRate":0.555556,"avgChangeRate":0.011483},{"month":8,"riseRate":0.555556,"avgChangeRate":0.046113},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.028471},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.074254},{"month":11,"riseRate":0.555556,"avgChangeRate":0.001387},{"month":12,"riseRate":0.444444,"avgChangeRate":0.03326}],"exchange":"NASDAQ","name":"Syndax Pharmaceuticals","nameEN":"Syndax Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.2","shortVersion":"4.32.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Syndax Pharmaceuticals(SNDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Syndax Pharmaceuticals,SNDX,Syndax Pharmaceuticals股票,Syndax Pharmaceuticals股票老虎,Syndax Pharmaceuticals股票老虎国际,Syndax Pharmaceuticals行情,Syndax Pharmaceuticals股票行情,Syndax Pharmaceuticals股价,Syndax Pharmaceuticals股市,Syndax Pharmaceuticals股票价格,Syndax Pharmaceuticals股票交易,Syndax Pharmaceuticals股票购买,Syndax Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Syndax Pharmaceuticals(SNDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Syndax Pharmaceuticals(SNDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}